
Sign up to save your podcasts
Or


Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
By cancerGRACE - H. Jack West, MD5
11 ratings
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?

2 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners